Theradiag Announces the Launch of Two New i-Tracker® Kits
19 Mai 2022 - 7:30AM
Business Wire
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a
company specializing in in vitro diagnostics and Theranostics,
today announces the launch of two additional kits in its i-Tracker®
tests range.
Theradiag is extending its range with two additional i-Tracker®
test kits: i-Tracker® Certolizumab and i-Tracker®
Anti-Certolizumab, all adapted to the i-Track10®, its random-access
automated system, and to the IDS-iSYS automated analyzer
manufactured by the IDS company.
The CE marking of these two new i-Tracker® kits has been
completed and their marketing has been declared to the French
National Agency for the Safety of Medicines and Health Products
(ANSM). The Certolizumab kits are dedicated to the monitoring of
biotherapies used in the treatment of chronic inflammatory diseases
such as rheumatoid arthritis, spondylarthritis and psoriasis, but
also Crohn's disease in the United States, in Canada and in
Switzerland at this stage. The i-Tracker® range now consists of 14
kits that can be used to treat a wide range of diseases.
Bertrand de Castelnau, CEO of Theradiag, commented: "We
are very pleased to announce the CE marking of these two new kits
which materializes the R&D dynamics present at Theradiag. This
range extension contributes to extend our main purpose, namely to
develop individualized therapeutic monitoring of even more
biotherapies for the benefit of patients."
Financial calendar:
- H1 2022 revenue, Monday July 18, 2022
- H1 2022 results, Monday September 19, 2022
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2021, the Company posted revenue of €11.1 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan. For more
information about Theradiag, please visit our website:
https://www.theradiag.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220518005724/en/
Theradiag Bertrand de Castelnau CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent / Quentin Massé Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Theradiag (EU:ALTER)
Historical Stock Chart
Von Apr 2023 bis Apr 2024